Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

EBS 01.08.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-15
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur EBS Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.14.2025 - Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

Recent Filings

  • 01.15.2025 - 8-K Current report
  • 01.15.2025 - EX-99.1 EX-99.1

GAITHERSBURG, Md.,Jan. 08, 2025(GLOBE NEWSWIRE) --Emergent BioSolutions(NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced thatJoe C. Papa, president and chief executive officer, will present at the 43rd AnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 15, 2025, at1:30 PM PST.

The audio link for Emergent's session may be accessedhereand will be live for up to 30 days.

The company’s slides will be made available at the time of the presentation on theInvestors sectionof the Emergent website.

AboutEmergent BioSolutionsAt Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we help protect public health, visit ourwebsiteand follow us onLinkedIn,X,Instagram,Apple PodcastsandSpotify.

Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com

Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com

Primary Logo

Source: Emergent BioSolutions

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com